Dr John Joseph Carroll, MD | |
Raf Lakenheath 48 Mdg/sghc, Unit 5115, Apo, AE 09461-5115 | |
(401) 323-4885 | |
Not Available |
Full Name | Dr John Joseph Carroll |
---|---|
Gender | Male |
Speciality | Orthopaedic Surgery |
Location | Raf Lakenheath 48 Mdg/sghc, Apo, Armed Forces Europe |
Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
Identifier | Type | State | Issuer |
---|---|---|---|
1558742999 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207X00000X | Orthopaedic Surgery | 29371 (Nebraska) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr John Joseph Carroll, MD Raf Lakenheath 48 Mdg/sghc, Unit 5115, Apo, AE 09461-5115 Ph: (314) 226-8286 | Dr John Joseph Carroll, MD Raf Lakenheath 48 Mdg/sghc, Unit 5115, Apo, AE 09461-5115 Ph: (401) 323-4885 |
News Archive
Tiny particles that can carry drugs and target cancer cells may offer treatment hope for those suffering with pancreatic cancer. New research to be presented in November at the American Association of Pharmaceutical Scientists (AAPS) Annual Meeting in Los Angeles reveals that tumor-penetrating microparticles (TPM) have been specifically designed to break through hard-to-infiltrate barriers and deliver drugs more effectively and efficiently than the standard form of chemotherapy such as those injected through a vein.
Life Technologies Corporation today announced that its scientists have teamed with researchers from Stanford University School of Medicine, and other institutions to discover a genomic component that plays a key role in promoting breast cancer progression. A study published today in the journal Nature details how levels of a specific kind of non-coding RNA molecule in primary breast tumors regulate metastasis and tumor invasiveness and may be an important target for cancer diagnosis and therapy.
Vertex Pharmaceuticals Incorporated announced that the Antiviral Drugs Advisory Committee to the U.S. Food and Drug Administration voted unanimously to recommend FDA approval of telaprevir for people with genotype 1 chronic hepatitis C.
BELLUS Health Inc. and Celtic Therapeutics announced today that a global confirmatory phase III clinical study was initiated on December 14, 2010 for KIACTA™ (eprodisate). KIACTA™ is a drug candidate being developed for the treatment of AA amyloidosis, a life-threatening orphan disease that occurs in patients with long-lasting inflammatory conditions, most commonly due to rheumatoid arthritis. The study is designed to confirm the safety and efficacy of KIACTA™ in preventing renal function decline in patients with AA amyloidosis.
In a groundbreaking study led by an eminent molecular biologist at Florida State University, researchers have discovered that as embryonic stem cells turn into different cell types, there are dramatic corresponding changes to the order in which DNA is replicated and reorganized.
› Verified 8 days ago
Dr. Gregory Lause, M.D. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: Landstuhl Regional Medical Center, Unit 33100, Apo, AE 09180 Phone: 314-590-5762 | |
Dr. Steven Wilding, M.D. Orthopedic Surgery Medicare: Not Enrolled in Medicare Practice Location: Landstuhl Regional Medical Center, Unit 33100, Apo, AE 09180 Phone: 314-590-8094 | |
Dr. Zackary Johnson, M.D. Orthopedic Surgery Medicare: Not Enrolled in Medicare Practice Location: Landstuhl Regional Medical Center, Unit 33100, Apo, AE 09180 Phone: 314-590-7010 | |
Tierney Shannon Grosskopf, M.D. Orthopedic Surgery Medicare: Medicare Enrolled Practice Location: Landstuhl Regional Medical Center, Unit 33100, Apo, AE 09180 Phone: 314-590-5762 | |
Brendon Bauer, M.D. Orthopedic Surgery Medicare: Medicare Enrolled Practice Location: Landstuhl Regional Medical Center Unit 33100, Apo, AE 09180 Phone: 314-590-7028 | |
Dr. David Randolph Peterson, MD Orthopedic Surgery Medicare: Not Enrolled in Medicare Practice Location: Landstuhl Regional Medical Center, Unit 33100, Apo, AE 09180 Phone: 314-590-8094 |